Yahoo Finance

Accuray (NASDAQ:ARAY) Third Quarter 2025 Results

Key Financial Results

• Revenue: US$113.2m (up 12% from 3Q 2024).

• Net loss: US$1.30m (loss narrowed by 80% from 3Q 2024).

• US$0.013 loss per share (improved from US$0.064 loss in 3Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Accuray Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 71%.

Looking ahead, revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the US are expected to grow by 8.1%.

Performance of the American Medical Equipment industry.

The company's shares are up 10% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Accuray (including 1 which is significant).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.